Denali Gains 26.6% in a Year: How Should You Play the Stock?
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
Nasdaq3d
DNLI Makes Bullish Cross Above Critical Moving Average
In trading on Tuesday, shares of Denali Therapeutics Inc (Symbol: DNLI) crossed above their 200 day moving average of $23.11, changing hands as high as $23.33 per share. Denali Therapeutics Inc ...
Nasdaq4d
Denali Gains 26.6% in a Year: How Should You Play the Stock?
Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...
ETF Daily News5d
Denali Therapeutics Inc. (NASDAQ:DNLI) Sees Significant Increase in Short Interest
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) was the recipient of a significant growth in short interest in the month of December.As of December 31st, there was short interest ...
Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...